REDWOOD CITY, Calif.–(BUSINESS WIRE)–Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine fibroids, announced today that medical device executive Nelson Whistance has been named Vice President of U.S. Sales. Mr. Whistance reports directly to the President and CEO, Christopher M. Owens.
“Nelson is a proven sales leader that has spent the majority of his medical device career driving commercial business in minimally invasive gynecologic surgery. He brings a strong combination of business acumen, process-oriented leadership, has exceptional clinical expertise and a track record of developing world class training programs for physicians and commercial teams, that will enable us to scale rapidly. Nelson will support our mission of creating an impactful and lasting improvement in the standard of care for women who suffer from symptomatic uterine fibroids,” Owens said. “As we are on the precipice of the full commercial launch of our Sonata® 2 next generation system, Nelson adds these critical elements to the executive leadership team along with his proven success in driving disruptive technology adoption in the U.S. and Canada.”
“I’m thrilled to be joining Gynesonics at such a critical inflection point, as we are rapidly expanding access to this groundbreaking technology in the U.S. and globally,” said Mr. Whistance. “The Sonata procedure is going to revolutionize the care of women with symptomatic uterine fibroids, and I’m honored to have been selected to build a world class sales organization that will live up to its promise.”
Prior to joining Gynesonics, Mr. Whistance has successfully grown businesses and led commercial teams for various healthcare companies in the United States and Canada. He has led sales teams in multiple product launches, partnered with physician leaders to drive site-of-care optimization and built top quality sales training and development programs.
Previously, Mr. Whistance was Vice President of Sales and Marketing for Prytime Medical Devices, supporting the commercial market adoption of the ER-REBOA™ Catheter portfolio. Prior to Prytime, Mr. Whistance held various positions in sales, sales field training and sales management for the surgical division of Hologic supporting the MyoSure® and NovaSure® gynecological technologies. Mr. Whistance has held various sales and leadership roles for American Medical Systems, Servier Canada Pharmaceuticals and Sysco Edmonton.
Mr. Whistance is a graduate of the University of Alberta, with a bachelor’s degree in Secondary Education.
About Sonata System
The Sonata System uses radiofrequency energy to ablate fibroids under real time sonography guidance from within the uterine cavity, utilizing the first and only intrauterine ultrasound transducer. The System includes a proprietary graphical user interface (SMART Guide), enabling the operator to target fibroids and optimize treatment. The Sonata system provides, incision-free transcervical access for a uterus-preserving fibroid treatment. This intrauterine approach is designed to avoid the peritoneal cavity. The Sonata System is CE marked and is approved for sale in the European Union and the United States.
Gynesonics is a women’s healthcare company focused on advancing women’s health, by developing minimally invasive, incision-free, uterus-preserving, transcervical technologies for diagnostic and therapeutic applications. Gynesonics has developed the Sonata System for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids. Gynesonics headquarters is in Redwood City, CA. For more information, go to www.gynesonics.com.
Rich Lanigan, Vice President, Global Commercialization, Gynesonics, firstname.lastname@example.org,
Nathan Abler, Dresner Corporate Services, email@example.com, (714) 742-4180